Push to Talk Telemedicine and M-Health
Convergence: Market Shares, Strategies, and Forecasts, Worldwide, 2013 to 2019
WinterGreen Research announces that it has published a new
study Push to Talk Telemedicine and M-Health Market Convergence Shares,
Strategy, and Forecasts, Worldwide, 2013 to 2019. The 2013 study has 791 pages,
278 tables and figures. Worldwide markets are poised to achieve significant
growth as the push to talk is used inside telemedicine systems and m-health
initiatives as a way to implement ruggedized handset communications for all
clinicians.
Worldwide
Tele-medicine and M-health PTT push to talk device market driving forces relate
to an overall trend toward clinical reimbursement addressing mobile health
initiative for chronic conditions. This trend promises to become prevalent as
people learn how to keep themselves healthier. Healthy behaviors such as
exercise, good diet and stress management have the potential to reverse aging
on a molecular level and partly restore the vitality of a person's cells.
To check out the complete table of
contents, visit: http://www.marketresearchreports.biz/analysis-details/push-to-talk-telemedicine-and-m-health-convergence-market-shares-strategies-and-forecasts-worldwide-2013-to-2019
Healthy
lifestyle choices can increase the length of DNA sequences found at the end of
a person's chromosomes. This shift toward wellness has stimulated the need for
better communication between clinicians and patients. New sensor technology
creates the opportunity for monitoring and for alerts to be send to and from at
risk people who are exercising.
PTT
telemedicine markets are poised to achieve significant growth as the existing
telemedicine systems merge with the smart phone systems of engagement to
provide a way to improve clinical care delivery to patients with chronic
disease, decreasing hospitalizations and visits to the emergency room. There is
a convergence of telemedicine and m-health as the patients become more
responsible for their own care delivery and their own health.
There
is a convergence of telemedicine and m-health as the patient uses push to talk
devices in telemonitoring situations where the sensor data is transmitted to a
facility, encouraging the patient to become more responsible for their own care
delivery and their own health. Push to talk devices are more rugged than
ordinary smart phones and are used in transport situations inside the hospital
and in ambulances.
Healthcare
patient, physician, and facility decision support markets are forecast based n
the broad availability of smartphones combined with the IBM Watson technology
that Watson offers Interactive Care Insights for Oncology. The cognitive
systems use insights gleaned from the deep experience of Memorial
Sloan-Kettering clinicians. Watson is positioned to permit clinicians to
provide individualized treatment.
According
to Susan Eustis, lead author of the WinterGreen Research team that prepared the
telemedicine market research study, "Telemedicine push to talk PTT markets
are evolving as smart phone devices find more uses during patient transport.
During emergency transport, sensors can provide monitoring that has not
previously been available. Differential diagnostic tools support differential
tele-medical treatment. The decision process take into account clinical
findings form the home monitoring devices and from symptoms verbally
communicated in a clinical services implementation."
Both
tele-medicine and m-health contribute to healthcare delivery in the home.
M-health will surely be delivered over the smart phone. Tele-medicine is
evolving toward smart phone device delivery as well. The cost of tele-medicine
for the US veterans administration is $1,600 per patient per annum. This is
substantially less than other NIC programs and nursing home care which can
easily run to $100,000 per annum. VHA's experience is that an enterprise-wide
home tele-medicine implementation is an appropriate and cost-effective way of
managing chronic care patients in both urban and rural settings.
Chronic
disease conditions are best treated early on when there is a change in patient
condition and an early intervention can make a difference. It is even better to
treat them in a wellness treatment environment before there are indications of
chronic disease, before symptoms develop, by addressing lifestyle issues early
on.
Telemedicine
delivered on proprietary devices is becoming obsolete. Kyocera is the market
leader in push to talk phones for telemedicine. The Honeywell / Samsung
strategic alliance represents the smart phone model that works. Telemedicine
market analysis indicates that the price points are way below device costs and
that companies are seeking to gain market share by working with clients.
Telemedicine
push to talk PTT dedicated device and software markets at $214 million in 2012
are anticipated to reach $4.4 billion by 2019. M-Health markets related to
telemedicine at $1.4 billion are anticipated to reach $1.5 trillion by 2019 due
to the leveraging of 8.5 billion smart phones and 5 billion connected tablet
devices all over the world.
Companies
Profiled
Market
Leaders
- Kyocera
- Samsung
Market
Participants
- Advocate Home Health
- Aerotel Medical Systems
- AMAC / Lifecomm
- American Heart Association (AHA)
- American TeleCare
- American Telemedicine Association
- Apple
- AT&T
- Athens Regional Home Health In-Home Telemonitoring Services
- Aurora Health Care
- Authentidate Holding
- Axon
- Bayer AG / Bayer HealthCare
- Biotronik
- Bosch Group
- Cardiocom
- Care Innovations / Intel® / GE
- Columbia University
- Connections365
- Continua
- Debiotech
- Debiotech and STMicroelectronics
- Evident Health Services
- FuzeBox
- Gemalto / Cinterion
- Home Healthcare Hospice and Community Services (HCS)
- Honeywell
- Infopia
- Johns Hopkins Launch Home Telemonitoring Education Initiative
- JSC CEM Technology
- Kiwok
- LG
- LifeMasters
- Logitech / LifeSize
- McKesson
- MedApps
- Medtronic
- Montefiore / CMO
- National Committee for Quality Assurance
- Nonin Medical, Inc.
- Partners Healthcare
- Philips
- Polycom
- ProConnections, Inc.
- REACH Health, Inc.
- RS TechMedic BV
- Samsung Apple
- Sandata Technologies, Inc.
- Selected Providers for Emergency Medical Care Monitoring
- Shield Association
- STMicroelectronics
- TeleAtrics™
- TouchPointCare
- Trifecta Technologies
- Tunstall Healthcare Group
- University of Houston
- Verizon Partners Healthcare
- Verizon Technologies
- Veteran's Administration (VA)
- VIDAVO S.A
- Vidyo
- Virtual Health
- Visiting Nurse Service Veteran's Administration (VA)
- Viterion
- Vodafone
- VRI
- Wellpoint NoninA&D Engineering / A&D Medical
- Windstream
Check
Out These Key Topics
- Push to Talk
- Telehealth
- Telemedicine
- Telemonitoring
- CMS Telemonitoring
- Heart disease treatment efficacy
- Care Management
- CMHCB
- Health Buddy System
- Medicare Monitoring
- Remote patient monitoring
- Heart failure mortality
- Health economics
- Heart Failure
- Heart Diseases
- Cardiovascular Diseases
- Behavior CHF patient
- Behavior Modification
- Telemedicine
- Hypertension monitoring
- Chronic heart disease telemonitoring
- Health care delivery efficacy
- Chronic Diseases Monitoring
- Health Services and Systems
- Telehealth
- DRE
- Health Monitoring
- Health Communication
- Aging
- Monitoring Technology
- Health engagement
- Medical innovation
- Mobile health
- Remote health monitoring
- Clinical communication
- Medical communication
- Tele-medicine
- Tele-health
- Tele-monitoring
- Chronic heart failure
- CHF
- Chronic heart disease
- Remote medical support
- Telepharmacy
- Seniors and health
- Diabetes Monitoring
- Tele Medicine
- Remote Patient Monitoring
- Chronic Heart Failure Mortality
- Health Economics
- Heart Failure
- Heart Diseases
- Cardiovascular Diseases
- Quality of Care
- American Medical Group Association
- Department of Veterans Affairs telemonitoring
- Chronic disease management
- Health Buddy System Healthcare telemonitoring
- Medicare telemonitoring
- Bosch telehealth
- Treatment Monitoring
Latest Reports:
Apoptosis
Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast,
2013 - 2019: http://www.marketresearchreports.biz/analysis-details/apoptosis-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019
Apoptosis
is a programmed natural process of cell death in the body which results from
natural stimuli in order to protect against viral infection, unusual cell
division and cells with damaged genetic material. However malfunctioning of
apoptosis can trigger uncontrolled and non regulated cell death related to
degenerative disorders such as Parkinson’s disease and Alzheimer’s. Defective
apoptosis process has been one of the most common and leading causes for cancer
wherein the affected cells instead of undergoing apoptosis continue to
proliferate and mutate. Thus development of apoptosis modulating drugs has
recently been witnessing spectacular growth in the treatment for cancer, CNS
diseases, and chronic inflammation or autoimmunity disorders.
The
global apoptosis market is categorized by:
Drug
class and consumables
- Direct apoptogens
- First generation indirect apoptogens
- Second generation indirect apoptogens
- Reagents and kits
Indications
- Cancer
- Cardiovascular
- Neurodegenerative diseases
Currently,
North America dominates the global apoptosis market and is followed by Europe
due to existence of huge potential for apoptosis modulating therapeutics and
rising popularity of targeted cancer therapy. Emerging economies of
Asia-Pacific, Latin America, Middle East and Africa are also expected to
undergo rapid growth in the apoptosis market due to the rising incidences of
cancer and unmet treatment needs in such developing regions.
Biological Drugs Market - Global Industry
Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019: http://www.marketresearchreports.biz/analysis-details/biological-drugs-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019
Biological
drugs are biological medical products whose active drug substance is extracted
by using living organism. The active substance is derived from living organism
by the usage of recombinant DNA technology. These drugs offer better treatment
solutions than synthetic drugs owing to greater accuracy and fewer side
effects. Biological drugs are mainly made of monoclonal antibodies (mAbs) that
help to fight with the disease. Monoclonal antibodies have the capability of
targeting specific area in the body that requires drug treatment hence
producing accurate results. Majorly biologic drugs are given for the treatment
of diseases such as HIV/AIDS, Alzheimer’s diseases, cancers and others. Moreover,
biologic drugs are also expected to find a solution for the large portion of
retired population which is more prone to chronic diseases.
Global
biological drugs market is growing at substantial rate owing to the drug
accuracy and increase in chronic diseases. In addition, biologic drugs have
shown a better outcome in long term and offer a better quality of life. There
are approximately 150 biologic drugs commercially available in the markets
which are being used to treat diseases such as asthma, irritable bowel
syndrome, rheumatoid arthritis, cancer and others. For example, Avastin for the
treatment of lung cancer and Cerezyme for Gaucher disease are commercially
available and cost about USD 100,000 and USD 300,000 per year respectively.
However, half of the biological drugs are about to lose their patent protection
and as a result cheaper alternative biogeneric products are expected to enter
in to the market. On the contrary, cost of the biologic drugs is one the major
restraining factor for the growth of this market. Biologic drugs are costly as
compared to other drugs but are likely to become cheaper in near future. Owing
to the potential benefits of the biologic drugs they have been put on fast
track FDA approval process.
This
research report analyzes this market depending on its market segments, major
geographies, and current market trends. Geographies analyzed under this
research report include
- North America
- Asia Pacific
- Europe
- Rest of the World
This
report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
About Us
MarketResearchReports.Biz is the most comprehensive
collection of market research reports. MarketResearchReports.Biz services are specially
designed to save time and money for our clients. We are a one stop solution for
all your research needs, our main offerings are syndicated research reports,
custom research, subscription access and consulting services. We serve all
sizes and types of companies spanning across various industries.
Contact
M/s
Sheela
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA
– Canada Toll Free: 866-997-4948
Blog:
http://industry-research-reports.blogspot.com/
No comments:
Post a Comment